Regeneron – Gene Therapy Approved for Hearing Loss

Summary Regeneron has received FDA approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy for genetic hearing loss caused by biallelic OTOF variants, marking a major milestone in sensory-organ gene therapy. What Happened The FDA approved Otarmeni for patients with ultra-rare genetic hearing loss driven…